Apheresis technologies and clinical applications: the 2007 International Apheresis Registry

PS Malchesky, AP Koo, CI Skibinski… - Therapeutic …, 2010 - Wiley Online Library
The developments in apheresis technologies and techniques and their clinical applications
worldwide are technologically, sociologically, and economically motivated. As in the past …

Apheresis technologies and clinical applications: the 2005 International Apheresis Registry

PS Malchesky, AP Koo, GA Roberson… - Therapeutic …, 2007 - Wiley Online Library
The developments in apheresis technologies and techniques and their clinical applications
worldwide are technologically, sociologically, and economically motivated. In past apheresis …

Apheresis technologies and clinical applications: the 2002 international apheresis registry

PS Malchesky, AP Koo, GA Roberson… - Therapeutic …, 2004 - Wiley Online Library
The developments in apheresis technologies and techniques and their clinical applications
worldwide are technologically, sociologically, and economically motivated. In past apheresis …

Apheresis technologies and clinical applications: the 2000 International Apheresis Registry

PS Malchesky, AP Koo, LA Rybicki - Therapeutic Apheresis, 2001 - Wiley Online Library
The developments in apheresis technologies and techniques and their clinical applications
worldwide are technologically, sociologically, and economically driven. In the past, …

Clinical trials of a cryoglobulin filter

GA Siami, W Wilkins, WJ Stone, AP Koo… - ASAIO …, 1994 - journals.lww.com
The authors report the results of clinical trials of a high capacity cryoglobulin filter (Cryofilter)
in seven patients with cryoglobulinemia unresponsive to high doses of prednisone or …

[PDF][PDF] Are selective macromolecule removal plasmapheresis systems useful for autoimmune diseases or hyperlipidemia?

PS Malchesky, A Kaplan, AP Koo, Y Sakurada… - ASAIO …, 1993 - researchgate.net
The development of extracorporeal blood treatment technologies, most notably the success
of dialysis in the treatment of renal failure, has stimulated the clinical investigation and …

[PDF][PDF] Myasthenia gravis therapy: immunoadsorbent may eliminate need for plasma products

K Sawada, PS Malchesky, AP Koo… - … Clinic Journal of …, 1993 - researchgate.net
MATERIALS AND METHODS To simulate a clinical treatment in vitro, a recirculating circuit
was used (Figure 1) and cell-free plasma was prepared. Plasma was procured by …

Methotrexate and rheumatoid arthritis

…, AM Segal, DJ Mazanec, AP Koo… - Annals of Internal …, 1989 - acpjournals.org
Excerpt To the Editor: We were pleased to read the review on methotrexate treatment for
rheumatoid arthritis by Tugwell and associates (1) and the position paper of the American …

Selective removal of anti‐acetylcholine receptor antibody in the low temperature operation of membrane plasma fractionation

…, PS Malchesky, M Zborowski, AP Koo - Journal of clinical …, 1992 - Wiley Online Library
The removal of anti‐acetylcholine receptor antibody (anti‐AChR Ab) by the plasma fractionator,
Kuraray EVAL 2A, was measured as a function of the filtration temperature (4 and 37C). …

Selective removal of high level cryoglobulins (CG) and immune complexes (IC) by a large pore membrane

…, Y Takeyama, H Harasaki, G Pence, AP Koo… - ASAIO …, 1987 - journals.lww.com
… Horiuchi, Takashi; Malchesky, Paul S.; Yamashita, Masato; Takeyama, Yoshifumi;
Harasaki, Hiroaki; Pence, Gail; Koo, Anna P.; Nosé, Yukihiko … ASAIO Transactions 33(3):p …